Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) (RASolute 305)
RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma
The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
This is a Phase 3, global, randomized, double-blind study designed to evaluate whether treatment with zoldonrasib in combination with Investigator choice of chemotherapy will improve progression-free survival or overall survival compared to placebo in combination with Investigator choice of chemotherapy when given to patients with previously untreated, 1L metastatic KRAS G12D-mutated pancreatic adenocarcinoma. Choice of chemotherapy (mFFX or GnP) will be at the discretion of the Investigator.
Patients will be randomized to one of two arms: zoldonrasib + Investigator choice of chemotherapy (Arm A) or placebo + Investigator choice of chemotherapy (Arm B).
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Revolution Medicines Study Director
- Telefonnummer: 1-844-2-REVMED
- E-post: medinfo@revmed.com
Studieorter
-
-
Arizona
-
Phoenix, Arizona, Förenta staterna, 85054
- Rekrytering
- Mayo Clinic Arizona
-
Kontakt:
- Bekaii-Saab
- Telefonnummer: 855-776-0015
-
Tucson, Arizona, Förenta staterna, 85719
- Rekrytering
- The University of Arizona Cancer Center-North Campus
-
Kontakt:
- Zimmerman
- Telefonnummer: 520-626-8286
- E-post: priscaz@arizona.edu
-
-
Connecticut
-
New Haven, Connecticut, Förenta staterna, 06511
- Rekrytering
- Yale University
-
Kontakt:
- Boateng
- Telefonnummer: 203-314-7948
- E-post: Kwasi.boateng@yale.edu
-
-
Florida
-
Gainesville, Florida, Förenta staterna, 32610
- Rekrytering
- University of Florida
-
Kontakt:
- Allegra
- Telefonnummer: 352-294-5691
- E-post: allisonallegra3@ufl.edu
-
Kontakt:
- Barnes
- Telefonnummer: 352-273-8020
- E-post: j.barnes1@ufl.edu
-
Jacksonville, Florida, Förenta staterna, 32224
- Rekrytering
- Mayo Clinic Florida
-
Kontakt:
- Babiker
- Telefonnummer: 855-776-0015
-
Tampa, Florida, Förenta staterna, 33612
- Rekrytering
- Moffitt Cancer Center
-
Kontakt:
- Kim
- Telefonnummer: 813-745-3691
- E-post: Cheyenne.Schneider@moffitt.org
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30318
- Rekrytering
- Piedmont Cancer Institute
-
Kontakt:
- Adams
- Telefonnummer: 678-298-3238
- E-post: kadams@piedmontcancerinstitute.com
-
Atlanta, Georgia, Förenta staterna, 30318
- Rekrytering
- Piedmont Healthcare
-
Kontakt:
- Mieri
- Telefonnummer: 404-425-1777
- E-post: Takiyyah.Hamilton@piedmont.org
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60637
- Rekrytering
- University of Chicago Medical Center
-
Kontakt:
- Desgardin
- Telefonnummer: 773-834-7188
- E-post: adesgard@bsd.uchicago.edu
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21287
- Rekrytering
- Johns Hopkins University
-
Kontakt:
- Apostol
- Telefonnummer: 410-502-7484
- E-post: giclinicaltrials@jhmi.edu
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02215
- Rekrytering
- Dana Farber Cancer Institute
-
Kontakt:
- Lindquist
- Telefonnummer: 857-215-2351
- E-post: DanielleA_Lindquist@DFCI.HARVARD.EDU
-
-
Minnesota
-
Rochester, Minnesota, Förenta staterna, 55905
- Rekrytering
- Mayo Clinic Rochester
-
Kontakt:
- Jazieh
- Telefonnummer: 855-776-0015
-
-
New Jersey
-
East Brunswick, New Jersey, Förenta staterna, 08816
- Rekrytering
- Astera Cancer Care
-
Kontakt:
- Yao
- Telefonnummer: ext 1012 732-390-7750
- E-post: eileen.peng@asterahealthcare.org
-
New Brunswick, New Jersey, Förenta staterna, 08901
- Rekrytering
- Rutgers Cancer University
-
Kontakt:
- DiOrio
- Telefonnummer: 732-235-2135
- E-post: kassie.diorio@rutgers.edu
-
-
New York
-
New York, New York, Förenta staterna, 10032
- Rekrytering
- Columbia University Irving Medical Center
-
Kontakt:
- Manji
- Telefonnummer: 212-342-5162
- E-post: cancerclinicaltrials@cumc.columbia.edu
-
-
North Carolina
-
Durham, North Carolina, Förenta staterna, 27710
- Rekrytering
- Duke Cancer Center
-
Kontakt:
- Currier
- Telefonnummer: 919-668-1861
- E-post: gi-oncology-cru@dm.duke.edu
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37232
- Rekrytering
- Vanderbilt-Ingram Cancer Center
-
Kontakt:
- Cardin
- Telefonnummer: 800-811-8480
- E-post: cip@vumc.org
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- Rekrytering
- University of Texas MD Anderson Cancer Center
-
Kontakt:
- Ross
- Telefonnummer: 713-794-1623
- E-post: GIClinicalTrials@mdanderson.org
-
-
-
-
-
Florence, Italien, 50134
- Rekrytering
- Azienda Ospedaliera Universitaria Careggi
-
Padova, Italien, 35128
- Rekrytering
- Instituto Oncologico Veneto - IRCCS
-
-
-
-
-
Nijmegen, Nederländerna, 6525
- Rekrytering
- Radboud UMC
-
-
-
-
-
London, Storbritannien, SW3 6JJ
- Rekrytering
- Royal Marsden Hospital
-
London, Storbritannien, EC1A 7BE
- Rekrytering
- St Bartholomew's Hospital - Barts Health NHS Trust
-
London, Storbritannien, W12 0HS
- Rekrytering
- Imperial College Healthcare NHS Foundation Trust - Hammersmith Hospital
-
-
-
-
-
Salzburg, Österrike, 05020
- Rekrytering
- Universitatsklinikum der PMU Salzburg Landeskrankenhaus
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- At least 18 years old and has provided informed consent.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Histologically or cytologically confirmed pancreatic adenocarcinoma.
- Diagnosis of metastatic disease ≤ 6 weeks prior to screening.
- Documented KRAS G12D mutation status.
- Measurable disease per RECIST v1.1.
- Adequate organ function (bone marrow, liver, kidney, coagulation).
- Able to take oral medications.
Exclusion Criteria:
- Prior treatment with systemic anticancer therapy in unresectable locally advanced or metastatic setting.
- Prior systemic RAS-targeted therapy any time prior to randomization.
- Presence of other known driver mutations with approved targeted therapies
- Active or known history of untreated central nervous system metastatic disease.
- Any conditions that may affect the ability to take or absorb study drug.
- Major surgery within 28 days prior to randomization.
- Patient is unable or unwilling to comply with protocol-required study visits or procedures.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Arm A: zoldonrasib + chemotherapy
study drug in combination with Investigator choice chemotherapy (mFFX or GnP) |
IV infusion oral tablets IV infusion IV infusion IV infusion IV infusion IV infusion |
|
Placebo-jämförare: Arm B: placebo + chemotherapy
placebo in combination with Investigator choice chemotherapy (mFFX or GnP) |
IV infusion IV infusion IV infusion IV infusion IV infusion IV infusion oral tablets |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Progression free survival (PFS)
Tidsram: Up to approximately 4 years
|
PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is assessed per response evaluation criteria in solid tumors (RECIST) v1.1 by Investigator. |
Up to approximately 4 years
|
|
Overall survival (OS)
Tidsram: Up to approximately 4 years
|
OS is defined as the time from randomization until death from any cause. |
Up to approximately 4 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
PFS per blinded independent central review (BICR)
Tidsram: Up to approximately 4 years
|
PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is assessed RECIST v1.1 by BICR. |
Up to approximately 4 years
|
|
Objective response rate (ORR)
Tidsram: Up to approximately 4 years
|
Objective response is defined as partial response (PR) or complete response (CR) as assessed per RECIST v1.1 by Investigator and BICR. |
Up to approximately 4 years
|
|
Duration of response (DOR)
Tidsram: Up to approximately 4 years
|
DOR is defined as time from first evidence of objective response (PR or CR) to disease progression or death due to any cause, whichever occurs first, as assessed by the investigator and BICR. |
Up to approximately 4 years
|
|
Incidence of adverse events (AEs)
Tidsram: Up to approximately 4 years
|
Percentage of patients with AEs as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5 |
Up to approximately 4 years
|
|
Changes in vital signs
Tidsram: Up to approximately 4 years
|
Number of patients with clinically significant changes in vital signs. |
Up to approximately 4 years
|
|
Changes in clinical laboratory test values
Tidsram: Up to approximately 4 years
|
Number of patients with changes from baseline in clinical laboratory test values |
Up to approximately 4 years
|
|
Health-related outcome assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Pancreatic Cancer Module (EORTC QLQ-PAN26) pain scale
Tidsram: Up to approximately 4 years
|
EORTC QLQ-PAN26 consists of 26 questions relating to disease symptoms, treatment side effects and emotional issues specific to pancreatic cancer. The pancreatic pain subscale assesses abdominal pain, back pain, and pain while lying down. Change in score from baseline in the pain subscale will be assessed with higher scores on the pain subscale indicating more severe pain and worsening function. |
Up to approximately 4 years
|
|
Quality of life as assessed with European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) global health status score
Tidsram: Up to approximately 4 years
|
EORTC QLQ-C30 consists of 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, pain, nausea/vomiting, dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties), and an overall scale for global health status. It uses a mix of 4-point scales and 7-point scales. Change from baseline in EORTC QLQ-C30 global health status will be assessed. Higher scores on functional scales reflect better functioning, whereas higher scores on symptom scales reflect higher symptom burden. |
Up to approximately 4 years
|
|
Concentration of zoldonrasib in Arm A
Tidsram: Up to Cycle 5 Day 1 (each cycle is 28 days)
|
Pre-dose trough and post-dose blood concentrations of zoldonrasib at selected visits. |
Up to Cycle 5 Day 1 (each cycle is 28 days)
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Sjukdomar i det endokrina systemet
- Neoplasmer efter plats
- Neoplasmer
- Neoplasmer i matsmältningssystemet
- Matsmältningssystemets sjukdomar
- Neoplasmer i endokrina körtel
- Bukspottkörtelsjukdomar
- Pankreatiska neoplasmer
- Organiska kemikalier
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Heterocykliska föreningar, 2-ring
- Heterocykliska föreningar, smältring
- Camptotecin
- Alkaloider
- Enzymer och koenzymer
- Koordinationskomplex
- Deoxycytidin
- Cytidin
- Pyrimidin nukleosider
- Pyrimidiner
- Formyltetrahydrofolat
- Tetrahydrofolat
- Folinsyra
- Pteriner
- Pteridiner
- Uracil
- Pyrimidinoner
- Koenzymer
- Oxaliplatin
- Irinotekan
- Gemcitabin
- Fluorouracil
- Leucovorin
- 130-nm albuminbunden paklitaxel
Andra studie-ID-nummer
- RMC-9805-305
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .